Arrhythmias & electrophysiology

Impact of obesity on procedural safety and 1-year outcomes after pulsed-field ablation for atrial fibrillation

EuropacePublished nationwide registry

Authors' conclusion

In this nationwide PFA cohort, higher BMI identified a more advanced AF phenotype and more extensive ablation strategies but was not independently associated with periprocedural complications or 1-year arrhythmia recurrence.

Study context

Population
Patients undergoing first-time AF ablation with a pentaspline pulsed-field ablation (PFA) catheterBody mass index (BMI) available in 4573 (87.6%)
Participants
5,223 patients
Exposure
Periprocedural complications and 1-year atrial arrhythmia recurrence across BMI categories
Outcome
Cardiometabolic burden, persistent AF, atrial size and ablation strategy with higher BMI
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

Higher BMI associated with greater cardiometabolic burden, more persistent AF, larger atria, fewer pulmonary vein isolation-only procedures and more additional lesion sets
all P < 0.001

Observational data: associations, not effects.

Further findings

1-year atrial arrhythmia recurrence by AF type, BMI < 35 vs ≥35 kg/m²

Paroxysmal AF: BMI < 35 kg/m²
13.8%
Paroxysmal AF: BMI ≥35 kg/m²
9.1%
Non-paroxysmal AF: BMI < 35 kg/m²
22.9%
Non-paroxysmal AF: BMI ≥35 kg/m²
23.3%
Recurrence driven mainly by AF type rather than obesity
  • Log-rank P = 0.925

Recurrence, severe obesity (multivariable adjustment) · 1 year

Severe obesity not associated with recurrence after multivariable adjustment: HR, 0.86
P = 0.299 (95% CI 0.65-1.14)
Similar findings when BMI analysed continuously
  • Comparator group of the HR not stated

Safety

Periprocedural complications, overall
1.0%
No significant difference across BMI categories

Original publication

Impact of obesity on procedural safety and 1-year outcomes after pulsed-field ablation for atrial fibrillation. Europace. Published 29 October 2026. doi:10.1093/europace/euag288

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.